ESG31 Jul 2026, 08:30 pm
Gland Pharma Submits BRSR Report for FY2025-26
AI Summary
Gland Pharma Ltd. has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, fulfilling the requirements of Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The BRSR is integrated into the company's Annual Report for FY2025-26 and is accessible on its website. All disclosures within the report are presented on a standalone basis and have received a reasonable level of assurance from DNV Business Assurance India Private Limited. The company's core business, pharmaceutical research, development, manufacturing, and marketing of complex injectables, constitutes 100% of its turnover.
Key Highlights
- Gland Pharma submitted its BRSR for FY2025-26.
- Report complies with SEBI Listing Regulations 34(2)(f).
- Disclosures are standalone, with reasonable assurance.
- Pharmaceuticals account for 100% of company turnover.
- BRSR is part of the Annual Report for FY2025-26.
Price Impact
More from GLAND